Comprehensive RNA dataset of tissue and plasma from patients with esophageal cancer or precursor lesions

publication published on 14 March 2022

Custom long non-coding RNA capture enhances detection sensitivity in different human sample types

publication published on 01 September 2021

A comprehensive dataset of TLX1 positive ALL-SIL lymphoblasts and primary T-cell acute lymphoblastic leukemias

Blocking abundant RNA transcripts by high-affinity oligonucleotides during transcriptome library preparation

Blood collection tube and RNA purification method recommendations for extracellular RNA transcriptome profiling: A large-scale pre-analytical variable performance evaluation

Charting extracellular transcriptomes in The Human Biofluid RNA Atlas

CiLiQuant: Quantification of RNA Junction Reads Based on Their Circular or Linear Transcript Origin

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients

Comprehensive benchmarking of single cell RNA sequencing technologies for characterizing cellular perturbation

Cross-platform digital PCR evaluation of bovine papilloma virus quantification: introducing PCR-ValiPal for Standardized guided assay validation

Custom long non-coding RNA capture enhances detection sensitivity in different human sample types

Data from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Data from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Dramatic impact of blood collection tube and RNA purification method on extracellular RNA transcriptomes

Equivalence of saliva RT-qPCR testing to nasal-throat/nasopharyngeal swab testing in the general practitioner’s setting to detect SARS-CoV-2

Evaluation of a novel respiratory virus inactivating buffer for parallel RT-qPCR and quick antigen testing

Evaluation of efficiency and sensitivity of 1D and 2D sample pooling strategies for SARS-CoV-2 RT-qPCR screening purposes

Exploring the extracellular transcriptome in seminal plasma for non-invasive prostate cancer diagnosis

Flexible Methods for Standard Error Calculation in digital PCR Experiments

Genome-wide study of the effect of blood collection tubes on the cell-free DNA methylome

HTSplotter: an end-to-end data processing, analysis and visualisation tool for chemical and genetic in vitro perturbation screening

Human Skeletal Muscle Fiber Heterogeneity Beyond Myosin Heavy Chains

Intact messenger RNA exists in human blood plasma and urine, and their purified macromolecular compartments

Large-scale benchmarking of circRNA detection tools reveals large differences in sensitivity but not in precision

Minimally invasive classification of pediatric solid tumors using reduced representation bisulfite sequencing of cell-free DNA: a proof-of-principle study

Minimally invasive classification of pediatric solid tumors using reduced representation bisulfite sequencing of cell-free DNA: a proof-of-principle study

On the utility of RNA sample pooling to optimize cost and statistical power in RNA sequencing experiments

On the utility of RNA sample pooling to optimize cost and statistical power in RNA sequencing experiments

On the utility of RNA sample pooling to optimize cost and statistical power in RNA sequencing experiments

Patient-specific alterations in blood plasma cfRNA profiles enable accurate classification of cancer patients and controls

Performance assessment of total RNA sequencing of human biofluids and extracellular vesicles

Performance evaluation of RNA purification kits and blood collection tubes in the Extracellular RNA Quality Control (exRNAQC) study

Probabilistic index models for testing differential expression in single cell RNA sequencing data

Recurrent chromosomal imbalances provide selective advantage to human embryonic stem cells under enhanced replicative stress conditions

SMARTer single cell total RNA sequencing

Supplementary Figure S1 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Figure S1 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Figure S2 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Figure S2 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Figure S3 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Figure S3 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Figure S4 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Figure S4 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Figure S5 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Figure S5 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Figure S6 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Figure S6 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Figure S7 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Figure S7 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Figure S7 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Materials & Methods from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Materials & Methods from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Table S1 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

Supplementary Table S1 from Targeted Therapy of <i>TERT</i>-Rearranged Neuroblastoma with BET Bromodomain Inhibitor and Proteasome Inhibitor Combination Therapy

The long non-coding RNASAMMSONis essential for uveal melanoma cell survival

The microRNA Landscape of Acute Beta Cell Destruction in Type 1 Diabetic Recipients of Intraportal Islet Grafts

When DNA gets in the way in RNA-seq experiments, a sequel